These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
119 related articles for article (PubMed ID: 7711280)
1. The relationship between pharmacokinetic behaviour of glycyrrhizin and hepatic function in patients with acute hepatitis and liver cirrhosis. Yamamura Y; Tanaka N; Santa T; Kotaki H; Aikawa T; Uchino K; Osuga T; Sawada Y; Iga T Biopharm Drug Dispos; 1995 Jan; 16(1):13-21. PubMed ID: 7711280 [TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic profiles of glycyrrhizin in patients with chronic hepatitis. Tanaka N; Yamamura Y; Santa T; Kotaki H; Uchino K; Sawada Y; Aikawa T; Osuga T; Iga T Biopharm Drug Dispos; 1993 Oct; 14(7):609-14. PubMed ID: 8251615 [TBL] [Abstract][Full Text] [Related]
3. The pharmacokinetics of glycyrrhizin and its restorative effect on hepatic function in patients with chronic hepatitis and in chronically carbon-tetrachloride-intoxicated rats. Yamamura Y; Kotaki H; Tanaka N; Aikawa T; Sawada Y; Iga T Biopharm Drug Dispos; 1997 Nov; 18(8):717-25. PubMed ID: 9373728 [TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic profile of glycyrrhizin in healthy volunteers by a new high-performance liquid chromatographic method. Yamamura Y; Kawakami J; Santa T; Kotaki H; Uchino K; Sawada Y; Tanaka N; Iga T J Pharm Sci; 1992 Oct; 81(10):1042-6. PubMed ID: 1432618 [TBL] [Abstract][Full Text] [Related]
5. [The pharmacokinetics of the glycyrrhizin and glycyrrhetic acid after intravenous administration of glycyrrhizin for the patients with chronic liver disease caused by type C hepatitis virus]. Takahashi M; Nakano S; Takeda I; Kumada T; Sugiyama K; Osada T; Kiriyama S; Toyoda H; Shimada S; Samori T Nihon Shokakibyo Gakkai Zasshi; 1995 Dec; 92(12):1929-36. PubMed ID: 8558777 [TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of glycyrrhizin after intravenous administration to rats. Tsai TH; Liao JF; Shum AY; Chen CF J Pharm Sci; 1992 Sep; 81(9):961-3. PubMed ID: 1432649 [TBL] [Abstract][Full Text] [Related]
7. Administration-route dependency of absorption of glycyrrhizin in rats: intraperitoneal administration dramatically enhanced bioavailability. Yamamura Y; Santa T; Kotaki H; Uchino K; Sawada Y; Iga T Biol Pharm Bull; 1995 Feb; 18(2):337-41. PubMed ID: 7742809 [TBL] [Abstract][Full Text] [Related]
8. [Preventive and therapeutic actions of glycyrrhizin, glycyrrhetic acid and crude saikosides on experimental liver cirrhosis in rats]. Zhao MQ; Han DW; Ma XH; Zhao YC; Yin L; Li CM Yao Xue Xue Bao; 1983 May; 18(5):325-31. PubMed ID: 6637483 [No Abstract] [Full Text] [Related]
9. Pharmacokinetics of intravenous glycyrrhizin after single and multiple doses in patients with chronic hepatitis C infection. van Rossum TG; Vulto AG; Hop WC; Schalm SW Clin Ther; 1999 Dec; 21(12):2080-90. PubMed ID: 10645755 [TBL] [Abstract][Full Text] [Related]
10. [The inhibitory effects of glycyrrhizin and glycyrrhetinic acid on the metabolism of cortisol and prednisolone--in vivo and in vitro studies]. Ojima M; Satoh K; Gomibuchi T; Itoh N; Kin S; Fukuchi S; Miyachi Y Nihon Naibunpi Gakkai Zasshi; 1990 May; 66(5):584-96. PubMed ID: 2384181 [TBL] [Abstract][Full Text] [Related]
11. [Treatment of non-A, non-B hepatitis with glycyrrhizin]. Ohta W; Iwamura K Nihon Rinsho; 1988 Dec; 46(12):2681-8. PubMed ID: 3149342 [No Abstract] [Full Text] [Related]
12. Effect of glycyrrhizin on lysis of hepatocyte membranes induced by anti-liver cell membrane antibody. Shiki Y; Shirai K; Saito Y; Yoshida S; Mori Y; Wakashin M J Gastroenterol Hepatol; 1992; 7(1):12-6. PubMed ID: 1543863 [TBL] [Abstract][Full Text] [Related]
13. Combined ursodeoxycholic acid and glycyrrhizin therapy for chronic hepatitis C virus infection: a randomized controlled trial in 170 patients. Tsubota A; Kumada H; Arase Y; Chayama K; Saitoh S; Ikeda K; Kobayashi M; Suzuki Y; Murashima N Eur J Gastroenterol Hepatol; 1999 Oct; 11(10):1077-83. PubMed ID: 10524635 [TBL] [Abstract][Full Text] [Related]
14. Prevention of hepatotoxic responses to chemicals by glycyrrhizin in rats. Shibayama Y Exp Mol Pathol; 1989 Aug; 51(1):48-55. PubMed ID: 2767217 [TBL] [Abstract][Full Text] [Related]
15. Intravenous glycyrrhizin for the treatment of chronic hepatitis C: a double-blind, randomized, placebo-controlled phase I/II trial. van Rossum TG; Vulto AG; Hop WC; Brouwer JT; Niesters HG; Schalm SW J Gastroenterol Hepatol; 1999 Nov; 14(11):1093-9. PubMed ID: 10574137 [TBL] [Abstract][Full Text] [Related]
16. Biliary excretion and enterohepatic cycling of glycyrrhizin in rats. Ichikawa T; Ishida S; Sakiya Y; Sawada Y; Hanano M J Pharm Sci; 1986 Jul; 75(7):672-5. PubMed ID: 3761168 [TBL] [Abstract][Full Text] [Related]
17. Combination therapy of glycyrrhizin withdrawal and human fibroblast interferon for chronic hepatitis B. Hayashi J; Kashiwagi S; Noguchi A; Ikematsu H; Tsuda H; Tsuji Y; Motomura M Clin Ther; 1989; 11(1):161-9. PubMed ID: 2497983 [TBL] [Abstract][Full Text] [Related]
18. Bioavailability study of glycyrrhetic acid after oral administration of glycyrrhizin in rats; relevance to the intestinal bacterial hydrolysis. Takeda S; Ishthara K; Wakui Y; Amagaya S; Maruno M; Akao T; Kobashi K J Pharm Pharmacol; 1996 Sep; 48(9):902-5. PubMed ID: 8910850 [TBL] [Abstract][Full Text] [Related]